Antibody-based therapeutics have revolutionized the treatment landscape in recent decades, with more than 170 approvals transforming care in oncology, autoimmunity, and infectious disease. The field continues to evolve with advances in engineering and design to enable clinical advances, and emerging tools like artificial intelligence (AI) hold great promise to accelerate antibody discovery and optimization to overcome remaining challenges. 

This meeting will explore the future of antibody engineering and AI applications, highlighting novel approaches such as antibody–drug conjugates with new payloads, conditionally activated antibodies to improve cancer therapy, strategies to enhance immune system engagement through bispecific and multispecific formats, and even engineering novel effector functions. The program will feature cutting-edge research spanning basic, translational, clinical, and industry perspectives, fostering collaboration across disciplines to drive the next generation of antibody therapeutics. 

Additionally, this conference will be co-located with the Keystone Symposium on “Emerging Cell Therapies” to enable cross-pollination of ideas, tools and technologies towards bioengineering the next-generation of transformational therapeutics.

In the video below, Dr. Paul Carter from Genentech, talks about why you should attend this meeting:

Additionally, check out the speaker highlights: